Global to push GA events into
skip to main content

Title: Anticancer therapy

A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.
Issue Date:
OSTI Identifier:
Patent Number(s):
Application Number:
Contract Number:
Resource Relation:
Patent File Date: 2015 Mar 26
Research Org:
STC.UNM, Albuquerque, NM (United States)
Sponsoring Org:
Country of Publication:
United States

Works referenced in this record:

Nephrotoxicity in Mice After Repeated Imaging Using 111In-Labeled Peptides
journal, May 2010
  • Melis, M.; Vegt, E.; Konijnenberg, M.
  • Journal of Nuclear Medicine, Vol. 51, Issue 6, p. 973-977
  • DOI: 10.2967/jnumed.109.074310

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
journal, November 2009
  • Rolleman, Edgar; Melis, Marleen; Valkema, Roelf
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 37, Issue 5, p. 1018-1031
  • DOI: 10.1007/s00259-009-1282-y

Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues
journal, July 2009
  • de Jong, Marion; Breeman, Wout; Kwekkeboom, Dik
  • Accounts of Chemical Research, Vol. 42, Issue 7, p. 873-880
  • DOI: 10.1021/ar800188e

Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats
journal, September 2006
  • Rolleman, Edgar; Krenning, Eric; Bernard, Bert
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, Issue 2, p. 219-227
  • DOI: 10.1007/s00259-006-0232-1

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
journal, April 2002
  • de Jong, Marion; Valkema, Roelf; Jamar, Francois
  • Seminars in Nuclear Medicine, Vol. 32, Issue 2, p. 133-140
  • DOI: 10.1053/snuc.2002.31027

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience
journal, April 2002
  • Valkema, Roelf; de Jong, Marion; Bakker, Willem H.
  • Seminars in Nuclear Medicine, Vol. 32, Issue 2, p. 110-122
  • DOI: 10.1053/snuc/2002.31025

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts
journal, February 2011
  • Walrand, Stephan; Barone, Raffaella; Pauwels, Stanislas
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, Issue 7, p. 1270-1280
  • DOI: 10.1007/s00259-011-1744-x

Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
journal, September 2010
  • Menda, Y.; O'Dorisio, M.; Kao, S.
  • Journal of Nuclear Medicine, Vol. 51, Issue 10, p. 1524-1531
  • DOI: 10.2967/jnumed.110.075226

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC
journal, December 2009
  • Sierra, Maribel; Agazzi, Alberto; Bodei, Lisa
  • Cancer Biotherapy & Radiopharmaceuticals, Vol. 24, Issue 6, p. 659-665
  • DOI: 10.1089/cbr.2009.0641

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
journal, April 2008
  • Bodei, Lisa; Cremonesi, Marta; Ferrari, Mahila
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, Issue 10, p. 1847-1856
  • DOI: 10.1007/s00259-008-0778-1

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide
journal, January 2008
  • Barone, Raffaella; Walrand, Stéphan; Konijnenberg, Mark
  • Nuclear Medicine Communications, Vol. 29, Issue 3, p. 283-290
  • DOI: 10.1097/MNM.0b013e3282f3d03e

Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors
journal, December 2006

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial
journal, September 2004

Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas
journal, February 2004
  • Bodei, Lisa; Handkiewicz-Junak, Daria; Grana, Chiara
  • Cancer Biotherapy & Radiopharmaceuticals, Vol. 19, Issue 1, p. 65-71
  • DOI: 10.1089/108497804773391694

Assessment of Hepatic Toxicity from Treatment with 90Y-SMT 487 (OctreoTherâ„¢) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases
journal, August 2003
  • Bushnell, David; Menda, Yusuf; Madsen, Mark
  • Cancer Biotherapy & Radiopharmaceuticals, Vol. 18, Issue 4, p. 581-588
  • DOI: 10.1089/108497803322287664

90Y-DOTA-D-Phe1-Try3- octreotide in therapy of neuroendocrine malignancies
journal, January 2002
  • Paganelli, G.; Bodei, L.; Handkiewicz Junak, D.
  • Biopolymers, Vol. 66, Issue 6, p. 393-398
  • DOI: 10.1002/bip.10349

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
journal, July 2001
  • Waldherr, C.; Pless, M.; Maecke, H.
  • Annals of Oncology, Vol. 12, Issue 7, p. 941-945
  • DOI: 10.1023/A:1011160913619

Yttrium-90 DOTATOC: first clinical results
journal, October 1999
  • Otte, A.; Herrmann, R.; Heppeler, A.
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 26, Issue 11, p. 1439-1447
  • DOI: 10.1007/s002590050476